VISTERRA, INC.
Monoclonal antibodies and scFv antibody fragments targeting specific RNA modifications
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2007
- Latest Form D
- $12.9M, May 2012
- Total capital
- $22.3M
- Federal grants
- $150K
- 1 award · 2016
- Rank in peer group#4 of 1449
- Private capital raised
- $22.1M
- 3 Form D · last May 2012
- 173 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 19
- 21 pending · first 2023
- Rank in peer group#51 of 1449
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · A Library of Immunoaffinity Reagents for RNA modifications$150K
- Private capital raisedForm D · SEC · 3rd filing$12.9M
- Private capital raisedForm D · SEC · 2nd filing$6M
- Private capital raisedForm D · SEC · 1st filing$3.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Federal grants#4 · top 1%
- Granted patents#51 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alan CraneDirectorNamed in SEC Form D filings
- Brian J.G. Pereira, M.D.Executive Officer, DirectorNamed in SEC Form D filings
- David J.G. ArkowitzExecutive OfficerNamed in SEC Form D filings
- Edward KaniaDirectorNamed in SEC Form D filings
- Kevin BittermanDirectorNamed in SEC Form D filings
- Ram SasisekharanDirectorNamed in SEC Form D filings
Show all 7 people
- Steven BruggerExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 19 granted of 40- PendingAntibody Molecules To C5AR1 And Uses ThereofUSPTOApplication 19409656
- PendingAntibody Molecules To April And Uses ThereofUSPTOApplication 18899795
- PendingHumanized Antibody Molecules To CD138 And Uses ThereofUSPTOApplication 19214961
Show all 40 patent records
- Antibody Molecules To C5AR1 And Uses ThereofSep 10, 2026 · Application 19409656Pending
- Antibody Molecules To April And Uses ThereofApr 30, 2026 · Application 18899795Pending
- Humanized Antibody Molecules To CD138 And Uses ThereofDec 18, 2025 · Application 19214961Pending
- Engineered Polypeptides And Uses ThereofSep 25, 2025 · Application 19227822Pending
- Antibody Molecules to C5AR1 and Uses ThereofSep 16, 2025 · US 12,415,865Granted
- Humanized Antibody Molecules To CD138 And Uses ThereofJun 24, 2025 · US 12,338,291Granted
- Humanized Complement 5A Receptor 1 Antibodies And Methods Of Use ThereofMay 29, 2025 · Application 19049925Pending
- INTERLEUKIN-2 Agents And Uses ThereofMay 13, 2025 · US 12,297,249Granted
- Humanized Complement 5A Receptor 1 Antibodies And Methods Of Use ThereofApr 1, 2025 · US 12,264,203Granted
- Nucleic Acid Molecules Encoding Antibodies To A Proliferation-inducing Ligand (april)Feb 27, 2025 · Application 18790750Pending
- INTERLEUKIN-2 Agents And Uses ThereofFeb 20, 2025 · Application 18933201Pending
- Humanized Complement 5A Receptor 1 Antibodies And Methods Of Use ThereofFeb 18, 2025 · US 12,227,587Granted
- Antibody Molecules To April And Uses ThereofFeb 6, 2025 · Application 18814058Pending
- Formulations Of Antibody Molecules To Influenza VirusJan 21, 2025 · US 12,202,885Granted
- Antibody Molecules to C5AR1 and Uses ThereofJan 7, 2025 · US 12,187,807Granted
- Antibody Molecules To Dengue Virus And Uses ThereofDec 26, 2024 · Application 18752260Pending
- Formulations Of Antibody Molecules To Dengue VirusNov 7, 2024 · Application 18420532Pending
- Antibody Molecule-drug Conjugates And Uses ThereofOct 17, 2024 · Application 18435809Pending
- Method Of Using Antibody Molecules To Detect A Proliferation-inducing Ligand (april)Sep 17, 2024 · US 12,091,451Granted
- Antibody Molecules To CD138 And Uses ThereofSep 12, 2024 · Application 18581992Pending
- INTERLEUKIN-2 Agents And Uses ThereofSep 10, 2024 · US 12,084,484Granted
- Antibody Molecules To Dengue Virus And Uses ThereofAug 6, 2024 · US 12,054,539Granted
- Ha Binding AgentsJul 2, 2024 · US 12,024,552Granted
- Binding Polypeptides And Methods Of Making The SameMay 2, 2024 · Application 18481497Pending
- Antibody Molecule-drug Conjugates And Uses ThereofApr 30, 2024 · US 11,969,476Granted
- Treatment Of Complement Mediated Diseases And Disorders With C3B AntibodiesApr 25, 2024 · Application 18470726Pending
- Antibody Molecules To CD138 And Uses ThereofApr 2, 2024 · US 11,945,868Granted
- Antibody Molecules To April And Uses ThereofMar 21, 2024 · Application 18305667Pending
- Formulations Of Antibody Molecules To Dengue VirusMar 5, 2024 · US 11,918,651Granted
- Humanized Complement 5A Receptor 1 Antibodies And Methods Of Use ThereofFeb 27, 2024 · US 11,912,781Granted
- Antibody Molecule-drug Conjugates And Uses ThereofFeb 6, 2024 · US 11,890,319Granted
- Engineered Polypeptides And Uses ThereofJan 2, 2024 · US 11,858,980Granted
- IMMUNOSILENCING Fc VARIANTSDec 28, 2023 · Application 18457687Pending
- Methods Of Using INTERLEUKIN-2 AgentsDec 7, 2023 · Application 18167529Pending
- Binding Polypeptides And Methods Of Making The SameNov 21, 2023 · US 11,820,979Granted
- IMMUNOSILENCING Fc VARIANTSNov 16, 2023 · Application 18052131Pending
- Engineered Antibody Molecules To CD138 And Uses ThereofNov 2, 2023 · Application 18058334Pending
- Antibody Molecules to C5AR1 and Uses ThereofOct 3, 2023 · US 11,773,179Granted
- Compositions And Methods For Treating And Preventing InfluenzaAug 17, 2023 · Application 17783966Pending
- Antibody Molecule-drug Conjugates And Uses ThereofAug 25, 2022 · Application 17497157Pending
Related companies, and why
- Cyrus Biotechnology, Inc.Similar federal contract value in Biotech · null in contracts
- POLARITYTE, INC.Similar federal contract value in Biotech · null in contracts
- Grace Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Noema PharmaSimilar federal contract value in Biotech · null in contracts
- Cerium Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- KallyopeSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .